Subscribe To
CDXC / ChromaDex Corporation (CDXC) CEO Rob Fried on Q4 2021 Results - Earnings Call Transcript
CDXC News
By Business Wire
October 31, 2023
ChromaDex to Report Third Quarter 2023 Financial Results on Wednesday, November 8, 2023
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #Bioscience--ChromaDex Corp. (NASDAQ:CDXC) (“the Company”) a global bioscience company dedicated to healthy more_horizontal
By Seeking Alpha
August 9, 2023
ChromaDex Corporation (CDXC) Q2 2023 Earnings Call Transcript
ChromaDex Corporation (NASDAQ:CDXC ) Q2 2023 Earnings Call Transcript August 9, 2023 4:30 PM ET Company Participants Kendall Knysch - Director, Media more_horizontal
By Business Wire
August 2, 2023
ChromaDex to Report Second Quarter 2023 Financial Results on Wednesday, August 9, 2023
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, announced th more_horizontal
By Business Wire
May 2, 2023
ChromaDex to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #Q1Earnings--ChromaDex Corp. (NASDAQ:CDXC) (“the Company”) a global bioscience company dedicated to healthy more_horizontal
By Seeking Alpha
March 8, 2023
ChromaDex Corporation (CDXC) Q4 2022 Earnings Call Transcript
ChromaDex Corporation (NASDAQ:CDXC ) Q4 2022 Earnings Conference Call March 8, 2023 4:30 PM ET Company Participants Tom Shumaker – LifeSci Advisors, more_horizontal
By Zacks Investment Research
March 8, 2023
ChromaDex (CDXC) Reports Q4 Loss, Lags Revenue Estimates
ChromaDex (CDXC) delivered earnings and revenue surprises of 33.33% and 0.40%, respectively, for the quarter ended December 2022. Do the numbers hold more_horizontal
By Business Wire
February 27, 2023
ChromaDex to Report Fourth Quarter and Fiscal Year 2022 Financial Results on Wednesday, March 8, 2023
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #earnings--ChromaDex Corp. (NASDAQ:CDXC) (“the Company”), a global bioscience company dedicated to healthy more_horizontal
By Zacks Investment Research
December 19, 2022
Down 9.6% in 4 Weeks, Here's Why ChromaDex (CDXC) Looks Ripe for a Turnaround
The heavy selling pressure might have exhausted for ChromaDex (CDXC) as it is technically in oversold territory now. In addition to this technical mea more_horizontal